Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Jan 3;3(1):e1919284.
doi: 10.1001/jamanetworkopen.2019.19284.

Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

Evan Kovac  1   2 , Sigrid V Carlsson  3   4   5 , Hans Lilja  4   6   7   8   9 , Jonas Hugosson  5 , Michael W Kattan  10 , Erik Holmberg  11 , Andrew J Stephenson  12
Affiliations
Randomized Controlled Trial

Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

Evan Kovac et al. JAMA Netw Open. .

Abstract

Importance: The use of prostate-specific antigen (PSA) screening for prostate cancer is controversial because of the risk of overdiagnosis and overtreatment of indolent cancers. Optimal screening strategies are highly sought.

Objective: To estimate the long-term risk of any prostate cancer and clinically significant prostate cancer based on baseline PSA levels among men aged 55 to 60 years.

Design, setting, and participants: This secondary analysis of a cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial uses actuarial analysis to analyze the association of baseline PSA levels with long-term risk of any prostate cancer and of clinically significant prostate cancer among men aged 55 to 60 years enrolled in the screening group of the trial between 1993 and 2001.

Exposure: Single PSA measurement at study entry.

Main outcomes and measures: Long-term risk of any prostate cancer and clinically significant prostate cancer diagnoses.

Results: There were 10 968 men aged 55 to 60 years (median [interquartile range] age, 57 [55-58] years) at study enrollment in the screening group of the PLCO Cancer Screening Trial who had long-term follow-up. Actuarial 13-year incidences of clinically significant prostate cancer diagnosis among participants with a baseline PSA of 0.49 ng/mL or less was 0.4% (95% CI, 0%-0.8%); 0.50-0.99 ng/mL, 1.5% (95% CI, 1.1%-1.9%); 1.00-1.99 ng/mL, 5.4% (95% CI, 4.4%-6.4%); 2.00-2.99 ng/mL, 10.6% (95% CI, 8.3%-12.9%); 3.00-3.99 ng/mL, 15.3% (95% CI, 11.4%-19.2%); and 4.00 ng/mL and greater, 29.5% (95% CI, 24.2%-34.8%) (all pairwise log-rank P ≤ .004). Only 15 prostate cancer-specific deaths occurred during 13 years of follow-up, and 9 (60.0%) were among men with a baseline PSA level of 2.00 ng/mL or higher.

Conclusions and relevance: In this secondary analysis of a cohort from the PLCO Cancer Screening Trial, baseline PSA levels among men aged 55 to 60 years were associated with long-term risk of clinically significant prostate cancer. These findings suggest that repeated screening can be less frequent among men aged 55 to 60 years with a low baseline PSA level (ie, <2.00 ng/mL) and possibly discontinued among those with baseline PSA levels of less than 1.00 ng/mL.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Calrsson reported receiving a lecture honorarium and travel support from Astellas Pharma outside the submitted work. Dr Lilja reported holding patents on assays for free prostate-specific antigen, intact prostate-specific antigen, and human kallikrein 2 and being named on a patent for a statistical method to detect prostate cancer that has been commercialized by OPKO Health. Dr Kattan reported receiving personal fees from Exosome Diagnostics and Stratify Genomics outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. 13-Year Kaplan-Meier Risk of Any Prostate Cancer Among Patients Aged 55 to 60 Years Enrolled in the Screening Group of the PLCO Cancer Screening Trial, Stratified by Baseline Prostate-Specific Antigen (PSA) Level
To convert PSA to micrograms per liter, multiply by 1.0. PLCO indicates Prostate, Lung, Colorectal, and Ovarian.
Figure 2.
Figure 2.. 13-Year Kaplan-Meier Risk of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years Enrolled in the Screening Arm of the PLCO Cancer Screening Trial, Stratified by Baseline Prostate-Specific Antigen (PSA) Level
To convert PSA to micrograms per liter, multiply by 1.0. PLCO indicates Prostate, Lung, Colorectal, and Ovarian.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer.
    Srinivasan S, Kryza T, Bock N, Tse BWC, Sokolowski KA, Janaththani P, Fernando A, Moya L, Stephens C, Dong Y, Röhl J, Alinezhad S, Vela I, Perry-Keene JL, Buzacott K, Nica R; IMPACT Study; Gago-Dominguez M; PROFILE Study Steering Committee; Schleutker J, Maier C, Muir K, Tangen CM, Gronberg H, Pashayan N, Albanes D, Wolk A, Stanford JL, Berndt SI, Mucci LA, Koutros S, Cussenot O, Sorensen KD, Grindedal EM, Travis RC, Haiman CA, MacInnis RJ, Vega A, Wiklund F, Neal DE, Kogevinas M, Penney KL, Nordestgaard BG, Brenner H, John EM, Gamulin M, Claessens F, Melander O, Dahlin A, Stattin P, Hallmans G, Häggström C, Johansson R, Thysell E, Rönn AC, Li W, Brown N, Dimeski G, Shepherd B, Dadaev T, Brook MN, Spurdle AB, Stenman UH, Koistinen H, Kote-Jarai Z, Klein RJ, Lilja H, Ecker RC, Eeles R; Practical Consortium; Australian Prostate Cancer BioResource; Clements J, Batra J. Srinivasan S, et al. Nat Commun. 2024 Nov 6;15(1):9587. doi: 10.1038/s41467-024-52472-6. Nat Commun. 2024. PMID: 39505858 Free PMC article.
  • Prostate tumor markers: diagnosis, prognosis and management.
    Lawisch GKDS, Dexheimer GM, Biolchi V, Seewald RA, Chies JAB. Lawisch GKDS, et al. Genet Mol Biol. 2024 Feb 26;46(3 Suppl 1):e20230136. doi: 10.1590/1678-4685-GMB-2023-0136. eCollection 2024. Genet Mol Biol. 2024. PMID: 38407310 Free PMC article.
  • Application and optimization of prostate-specific antigen screening strategy in the diagnosis of prostate cancer: a systematic review.
    Zhang Z, Tian A, Che J, Miao Y, Liu Y, Liu Y, Xu Y. Zhang Z, et al. Front Oncol. 2024 Jan 9;13:1320681. doi: 10.3389/fonc.2023.1320681. eCollection 2023. Front Oncol. 2024. PMID: 38264758 Free PMC article.
  • A new approach to prostate cancer screening.
    Filella X, González Á, Augé JM, Barco A, Carbonell R, Gaspar MJ, Martínez-Peinado A, Barrios CP, Sánchez-Carbayo M, Santotoribio JD, Trapé J; Comisión de Marcadores Biológicos de Cáncer, SEQCML. Filella X, et al. Adv Lab Med. 2023 Aug 3;4(3):207-211. doi: 10.1515/almed-2023-0082. eCollection 2023 Sep. Adv Lab Med. 2023. PMID: 38075179 Free PMC article.
  • Una nueva perspectiva en el cribado del cáncer de próstata.
    Filella X, González Á, Augé JM, Barco A, Carbonell R, Gaspar MJ, Martínez-Peinado A, Pérez Barrios C, Sánchez-Carbayo M, Santotoribio JD, Trapé J. Filella X, et al. Adv Lab Med. 2023 Jul 21;4(3):212-217. doi: 10.1515/almed-2023-0034. eCollection 2023 Sep. Adv Lab Med. 2023. PMID: 38075164 Free PMC article. Spanish.
See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):-. doi:10.3322/caac.21551 - DOI - PubMed
    1. Loeb S, Bjurlin MA, Nicholson J, et al. . Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046-1055. doi:10.1016/j.eururo.2013.12.062 - DOI - PMC - PubMed
    1. Moyer VA; US Preventive Services Task Force . Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120-134. doi:10.7326/0003-4819-157-2-201207170-00459 - DOI - PubMed
    1. Grossman DC, Curry SJ, Owens DK, et al. ; US Preventive Services Task Force . Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913. doi:10.1001/jama.2018.3710 - DOI - PubMed
    1. Mahal BA, Butler S, Franco I, et al. . Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015. JAMA. 2019;321(7):704-706. doi:10.1001/jama.2018.19941 - DOI - PMC - PubMed

Publication types